Pandemic Influenza Preparedness Framework 1 January – 31 December 2018 ANNUAL PROGRESS REPORT WHO/WHE/IHM/PIP/2019.1 © World Health Organization 2019. Some rights reserved. This work is available under the Creative Commons Attribution- NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. Pandemic Influenza Preparedness Framework: Progress Report 2018. Geneva: World Health Organization; 2019 (WHO/WHE/IHM/ PIP/2019.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data. CIP data are available at http://apps.who.int/iris. Sales, rights and licensing. To purchase WHO publications, see http://apps.who.int/bookorders. To submit requests for commercial use and queries on rights and licensing, see http://www.who.int/about/licensing. Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user. General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use. Printed in Switzerland INTRODUCTION The Pandemic Influenza Preparedness (PIP) Framework is an innovative public health instrument that brings together Member States, industry, other stakeholders and WHO to implement a global approach to pandemic influenza preparedness and response. The key goals include: to improve and strengthen the sharing of influenza viruses with human pandemic potential; and to increase the access of developing countries to vaccines and other pandemic response supplies. The Framework includes a benefit-sharing mechanism called the Partnership Contribution (PC). The PC is collected as an annual cash contribution from influenza vaccine, diagnostic, and pharmaceutical manufacturers that use the WHO Global Influenza Surveillance and Response System (GISRS). Funds are allocated for: (a) pandemic preparedness capacity building; (b) response activities during the time of a pandemic; and (c) PIP Secretariat for the management and implementation of the Framework. For pandemic preparedness capacity building, activities are implemented according to six outputs under one outcome in the High Level Implementation Plan (HLIP) II 2018-2023. The technical and financial investments of countries and other partners, including GISRS, play a critical role in advancing pandemic preparedness alongside PC investments. Collectively, resources are used to strengthen pandemic preparedness systems, knowledge and capacities. We thank countries and partners for their important role and contribution. The progress made and successes achieved are a result of joint collaboration on common objectives. This report addresses the recommendation from the 2016 PIP Review that WHO develop a progress report that presents overall success metrics and infographics to illustrate progress in PIP Framework implementation. The report is published twice a year: once as a semi-annual report and once as an annual report. Technical and financial implementation for HLIP II and the PIP Secretariat are presented. Milestones are measured every six months and indicators are measured yearly. All data are presented cumulatively from 1 January 2018. For financial implementation, progress is reported against biennial workplan allocations. Figures presented exclude WHO Programme Support Costs (PSC) unless otherwise stated. For the mid-year reports, income, expenditures and encumbrances are presented, and are based on WHO’s financial tracking system (GSM). For annual reports, income and expenditures are presented, in line with the yearly WHO Interim Certified Financial Statement (ICFS). Many staff across WHO Clusters and Departments in all Major Offices support the implementation of the PIP Framework. Without their work, dedication and collaboration, there would be no progress to report on. We extend our sincere thanks to these staff for their invaluable work. The report is structured as a series of infographics as follows: • PIP Framework implementation overview (pages 6 – 7) • Technical and financial implementation progress (pages 8 – 18) • Financial report including ICFS - Annex A (reported annually only) ACRONYMS & ABBREVIATIONS AFR AG AMR BM BOD CC CRP CVV DFID DG EB EMR DEP EQAP EUR GIP GISRS GSD HAI HLIP ICFS IDP ILI IPPP ISID ISST IVPP IVTM L&S LMIC MS NIC WHO African Region Advisory Group WHO Region of the Americas Biological Material Burden of Disease Collaborating Centre Collaborative Registration Procedure Candidate Vaccine Virus Department for International Development (United Kingdom) Director-General Executive Board WHO Eastern Mediterranean Region Planning for Deployment External Quality Assessment Programme WHO European Region Global Influenza Programme Global Influenza Surveillance and Response System Genetic Sequence Data Human Animal Interface High-Level Implementation Plan Interim Certified Financial Statement Institutional Development Plan Influenza-like Illness Influenza Pandemic Preparedness Planning International Society for Infectious Diseases Infectious Substances Shipping Training Influenza Virus with Pandemic Potential Influenza Virus Traceability Mechanism Laboratory and Surveillance Capacity Building Low and Middle Income Countries Member State National Influenza Centre NITAG NRA NVDP PC PCR PIP PIRM PISA PQ PSC QMS RCCE REG RO RRT SAGE SARI SEAR SFP SMTA2 TAG TOR UNICEF US CDC US HHS VCM WER WHA WPR WHO National Immunization Technical Advisory Groups National Regulatory Authority National Vaccine Deployment Plan Partnership Contribution Polymerase Chain Reaction Pandemic Influenza Preparedness Pandemic Influenza Risk Management Pandemic Influenza Severity Assessment Prequalification Programme Support Costs Quality Management Systems Risk Communications and Community Engagement Regulatory Capacity Building Regional Office Rapid Response Teams Strategic Advisory Group of Experts Severe Acute Respiratory Infection WHO South-East Asia Region Shipping Fund Project Standard Material Transfer Agreement 2 Technical Advisory Group Terms of Reference United Nations Children’s Fund United States Centers for Disease Control and Prevention United States Department of Health and Human Services Vaccine Composition Meeting Weekly Epidemiological Record World Health Assembly WHO Western Pacific Region World Health Organization 5Pandemic Influenza Preparedness Framework | ANNUAL PROGRESS REPORT | 1 January – 31 December 2018 IMPLEMENTATION OVERVIEW 6 Pandemic Influenza Preparedness Framework | ANNUAL PROGRESS REPORT | 1 January – 31 December 2018 PIP PC collection PIP PC financial implementation PIP Framework outcome indicators Improved global pandemic influenza preparedness and response through the implementation of the PIP Framework PIP SECRETARIAT BIENNIAL BUDGET: $6.8M FUNDED: $2.8M IMPLEMENTED: $2.4M RESPONSE TOTAL IN RESERVE (WITH PSC & 2018 INTEREST): $46.7M PERCENTAGE OF TOTAL PC RECEIVED BY YEAR OF INVOICE OUTCOME a In 2012, contributions were made voluntarily b Figure includes PSC. PC collection for previous unpaid contributions and 2018 invoices is in process $170M CONTRIBUTED BY INDUSTRY b % of Member States with zoonotic influenza cases sharing IVPPs with GISRS (N=4) % of PC recipient Member States reporting to FluNet (sustainability indicator) (N=37)1 % of PC recipient Member States reporting to FluID (N=37)1 % of Member States with BOD estimates considered by NITAG (N=19) No. of PC recipient Member States that have implemented regulatory approach % of PC recipient Member States that developed or updated a pandemic influenza preparedness plan (N=40)1 % of companies reached to negotiate that signed an SMTA2 (N=32) % of Partnership Contributions received in the year of invoice (N=$28M) N/A 84% 51% N/A 0 30% 34% N/A N/A ≥85% 60% 30% 10 60% 50% 100% 75% 89% 73% 16% 6 35% 38% 54% Indicator 2017 Baseline 2018 Status 2019 Target IMPLEMENTATION BY HLIP II OUTPUT US$ in thousands 20,000 15,000 10,000 5,000 - L&S REG BOD RCCE IPPP DEP T A R G E T 28M / Y E A R LEGEND Biennial budget Funded Implemented 3,000 2,000 1,000 - 3,000 2,000 1,000 - 3,000 2,000 1,000 - 3,000 2,000 1,000 - 3,000 2,000 1,000 - FUNDED: $16M IMPLEMENTED: $11.4M PREPAREDNESS BIENNIAL BUDGET: $31M 30 25 20 15 10 5 0 M IL LI O N U S$ 2013 2014 2015 2016 2017 2018 98% 96% 98% 97% 97% 54% 2012 a 7Pandemic Influenza Preparedness Framework | ANNUAL PROGRESS REPORT | 1 January – 31 December 2018 PIP Biological Materialsa shared PIP BMs RECORDED IN IVTM SMTA2 WITH VACCINE & ANTIVIRAL MANUFACTURERS >75M >5M and <75M <5M Large / multi-national manufacturers Medium-sized manufacturers Small manufacturers SMTA2 WITH DIAGNOSTIC MANUFACTURERS & ACADEMIC AND RESEARCH INSTITUTIONS TREATMENT COURSES OF ANTIVIRALS DOSES SMTA2 WITH ACADEMIC & RESEARCH INSTITUTIONS BENEFIT-SHARING OFFERS ACADEMIC & RESEARCH INSTITUTIONS pandemic production pandemic production pandemic production SMTA2 PIP Framework governance a For definition of ‘PIP Biological Materials’, see PIP Framework Section 4.1 10M NEW: SYRINGES 25M >400M 66 29 INFLUENZA VIRUSES WITH PANDEMIC POTENTIAL (IVPP) RECORDED IN THE INFLUENZA VIRUS TRACEABILITY MECHANISM (IVTM) TOTAL TO DATE: 12 MONTHS: INFLUENZA VIRUSES WITH PANDEMIC POTENTIAL RECORDED IN THE IVTM 1239 235 >75M pandemic production or multi-national companiest >5M and <75M pandemic production or medium-sized companies <5M pandemic production or small companies DOSES SECURED 380M Large / multi-national manufacturers Medium-sized manufacturers Small manufacturers DOSES SECURED 40M 405M DOSES SECURED DOSES SECURED 0 CONCLUDED CONCLUDED OF6 106OF6 CONCLUDED SMTA2 INFLUENZA VIRUSES WITH PANDEMIC POTENTIAL (IVPP) RECORDED IN THE INFLUENZA VIRUS TRACEABILITY MECHANISM (IVTM) TOTAL TO DATE: 12 MONTHS: INFLUENZA VIRUSES WITH PANDEMIC POTENTIAL RECORDED IN THE IVTM 1239 235 >75M pandemic production or multi-national companiest >5M and <75M pandemic production or medium-sized companies <5M pandemic production or small companies DOSES SECURED 380M Large / multi-national manufacturers Medium-sized manufacturers Small manufacturers DOSES SECURED 40M 405M DOSES SECURED DOSES SECURED 0 CONCLUDED CONCLUDED OF6 106OF6 CONCLUDED SMTA2 DIAGNOSTIC KITS 250,000 INFLUENZA VIRUSES WITH PANDEMIC POTENTIAL (IVPP) RECORDED IN THE INFLUENZA VIRUS TRACEABILITY MECHANIS (IVTM) TOTAL TO DATE: 12 MONTHS: INFLUENZA VIRUSES WITH PANDEMIC POTENTIAL RECORDED IN THE IVTM 1239 235 >75M pandemic production or multi-national companiest >5M and <75M pandemic production or medium-sized companies <5M pandemic production or small companies DOSES SECURED 380M L ge / multi-national manufacturers Medium-sized manufacturers Small manufacturers DOSES SECURED 40M 405M DOSES SECURED DOSES SECURED 0 CONCLUDED CONCLUDED OF6 106OF6 CONCLUDED SMTA2 INFLUENZA VIRUSES WITH PANDEMIC POTENTIAL (IVPP) RECORDED IN THE INFLUENZA VIRUS TRACEABILITY MECHANISM (IVTM) TOTAL TO DATE: 12 MONTHS: INFLUENZA VIRUSES WITH PANDEMIC POTENTIAL RECORDED IN THE IVTM 239 235 >75M pandemic production or multi-national companiest >5M and <75M pandemic production or medium-sized companies <5M pandemic production or small companies DOSES SECURED 380M Large / multi-national manufacturers Medium-sized man facturers Small manufacturers DOSES SECURED 40M 405M DOSES SECURED DOSES SECURED 0 CONCLUDED CONCLUDED OF 6 10 6OF6 CONCLUDED SMTA2 INFLUENZA VIRUSES WITH PANDEMIC POTENTIAL (IVPP) RECORDED IN THE INFLUENZA VIRUS TRACEABILITY MECHANISM (IVTM) TOTAL TO DATE: 12 MONTHS: INFLUENZA VIRUSES WITH PANDEMIC POTENTIAL RECORDED IN THE IVTM 1239 235 >75M pandemic production or multi-national companiest >5M and <75M pandemic production or medium-sized companies <5M pandemic production or small companies DOSES SECURED 380M Large / multi-national manufacturers Medium-sized manufacturers Small manufacturers DOSES SECURED 40M 405M DOSES SECURED DOSES SECURED 0 CONCLUDED CONCLUDED OF6 106OF6 CONCLUDED SMTA2 INFLUENZA VIRUSES WITH PANDEMIC POTENTIAL (IVPP) RECORDED IN THE INFLUENZA VIRUS TRACEABILITY MECHANISM (IVTM) TOTAL TO DATE: 12 MONTHS: INFLUENZA VIRUSES WITH PANDEMIC POTENTIAL RECORDED IN THE IVTM 1239 235 >75M pandemic production or multi-national companiest >5M and <75M pandemic production or medium-sized companies <5M pandemic producti n or small companies DOSES SECURED 380M Large / multi-national manufacturers Medium-sized manufacturers Small manufacturers DOSES SECURED 40M 405M DOSES SECURED DOSES SECURED 0 CONCLUDED CONCLUDED OF6 106OF6 CONCLUDED SMTA2 INFLUENZA VIRUSES WITH PANDEMIC POTENTIAL (IVPP) RECORDED IN THE INFLUENZA VIRUS TRACE BILITY MECHANISM (IVTM) TOTAL TO DATE: 12 MONTHS: INFLUENZA VIRUSES WITH PANDEMIC POTENTIAL RECORDED IN THE IVTM 1239 235 >75M pandemic production or multi-national companiest >5M and <75M pandemic production or medium-sized companies <5M pandemic production or small companies DOSES SECURED 380M Large / multi-national manufacturers Medium-sized manufacturers Small manufacturers DOSES SECURED 40M 405M DOSES SECURED DOSES SECURED 0 CONCLUDED CONCLUDED OF6 106OF6 CONCLUDED SMTA2 INFLUENZA VIRU ES WITH PANDEMIC POTENTIAL (IVPP) RECOR ED IN THE INFLUENZA VIRUS TRACEABILITY MECHANISM (IVTM) OTAL TO DATE: 12 MONTHS: INFLUENZA VIRU ES WITH PANDEMIC POTENTIAL RECOR ED IN THE IVTM 1239 235 >75M pandemic producti n or multi-national companiest >5M and <75M pandemic producti n or medium-sized companies <5M pandemic production or small companies DO ES SECURED 380M Large / multi-national man facturers Medium-sized nufacturers Small manufacturers DO ES SECURED 40M 405M DO ES SECURED DO ES SECURED 0 CONCLU ED CONCLU ED OF6 106OF6 CONCLU ED SMTA2 INFLUENZA VIRUSES WITH PANDEMIC PO ENTIAL (IV P) RECORDED IN THE INFLUENZA VIRUS TR CEABILITY MECHANISM (IVTM) TOTAL TO DATE: 12 MONTHS: INFLUENZA VIRUSES WITH PANDEMIC PO ENTIAL RECORDED IN THE IVTM >75M pandemic production or multi-national companiest >5M and <75M pandemic production or medium-sized companies <5M pandemic production or small companies DOSES SECURED Large / multi-national manufactu ers edium-sized anufactu ers Sma l manufactu ers DOSES SECURED DOSES SECURED DOSES SECURED CONCLUDED ONCLUDED OF OF ONCLUDED SMTA2 INFLUENZA VIRUSES WITH PANDEMIC POTENTIAL (IVPP) RECORDED IN THE INFLUENZA VIRUS TRACEABILITY MECHANISM (IVTM) TOTAL TO DATE: 12 MONTHS: INFLUENZA VIRUSES WITH PANDEMIC POTENTIAL RECORDED IN THE IVTM 1239 235 >75M pandemic production or multi-national companiest >5M and <75M pandemic production or medium-sized companies <5M pandemic production or small companies DOSES SECURED 380M Large / multi-national manufacturers Medium-sized manufacturers Small manufacturers DOSES SECURED 40M 405M DOSES SECURED DOSES SECURED 0 CONCLUDED CONCLUDED OF6 106OF6 CONCLUDED SMTA2 VIRUS SUBTYPES RECORDED: A(H1), A(H3), A(H5), A(H7), A(H9) PIP BMs RECORDED FROM 1 SEPTEMBER 2017 TO 31 AUGUST 2018: 184INFLUENZA VIRUSES WITH PANDEMIC POTENTIAL (IVPP) RECORDED IN THE INFLUENZA VIRUS TRACEABILITY MECHANISM (IVTM) TOTAL TO DATE: 12 MONTHS: INFLUENZA VIRUSES WITH PANDEMIC POTENTIAL RECORDED IN THE IVTM 1239 235 >75M pandemic production or multi-national companiest >5M and <75M pandemic production or medium-sized companies <5M pandemic production or small companies DOSES SECURED 380M Large / multi-national manufacturers Medium-sized manufacturers Small manufacturers DOSES SECURED 40M 405M DOSES SECURED DOSES SECURED 0 CONCLUDED CONCLUDED OF6 106OF6 CONCLUDED SMTA2 INFLUENZA VIRUSES WITH PANDEMIC POTENTIAL (IVPP) RECORDED IN THE INFLUENZA VIRUS TRACEABILITY MECHANISM (IVTM) TOTAL TO DATE: 12 MONTHS: INFLUENZA VIRUSES WITH PANDEMIC POTENTIAL RECORDED IN THE IVTM 1239 235 >75M pandemic production or multi-national companiest >5M and <75M pandemic production or medium-sized companies <5M pandemic production or small companies DOSES SECURED 380M Large / multi-national manufacturers Medium-sized manufacturers Small manufacturers DOSES SECURED 40M 405M DOSES SECURED DOSES SECURED 0 CONCLUDED CONCLUDED OF6 106OF6 CONCLUDED SMTA2 TOTAL SINCE 1 DECEMBER 2012: 844 On 11-13 April and 17-19 October 2018, the PIP Advisory Group held its meetings in Geneva, which included consultations with industry and other PIP Framework stakeholders. On 10 April 2018, the Secretariat held an Information Session on GISRS and the PIP Framework. The session was attended by more than 40 Member States and a wide range of stakeholders. The webcast from the session can be found at: http://www.who.int/influenza/pip/10_April_Info_Session/en/ The Secretariat circulated a draft Analysis on the scope of the PIP Framework as requested by the World Health Assembly in Decision 70(10). This draft was discussed by Member States and stakeholders at the 15-16 October 2018 consultation on the implementation of Decision WHA70(10)8b. The final text was submitted for discussion by the 144th WHO Executive Board in 2019. 8 Pandemic Influenza Preparedness Framework | ANNUAL PROGRESS REPORT | 1 January – 31 December 2018 IMPLEMENTATION PROGRESS 9Pandemic Influenza Preparedness Framework | ANNUAL PROGRESS REPORT | 1 January – 31 December 2018 IMPLEMENTED $2.3M countries from regions participated countries from regions participated countries from regions participated PISA trainings completed • 54 countries were trained in influenza severity assessment. WHO is supporting countries to establish thresholds, analyse and share their assessments. • 36 countries are strengthening surveillance and laboratory core capacities, including through trainings for RRT, influenza sentinel surveillance and outbreak investigation. • 41 human animal interface activities including risk assessments, coordination meetings and trainings were conducted for zoonotic influenza. • In addition, 9 influenza courses are now available at OpenWHO.org Outbreak detection & response trainings Meetings, workshops, joint investigation & risk assessments DELIVERABLE A Risk and severity of influenza, including at the human-animal interface, are routinely assessed MILESTONES INDICATORS HIGHLIGHTS Number of risk assessments published 10 1330 34 Number of MS reporting to PISA Laboratory & surveillance OUTPUT: National influenza L&S systems contribute to GISRS for timely risk assessment & response measure BIENNIAL BUDGET: $20.5M | IMPLEMENTED: $5.2M TARGET TARGETBASELINE STATUS PENDING STATUS PENDING BASELINE 18 41 43 3 36 5 83 6 2 32% 68% OUTPUT READING GUIDE Deliverable name Proportion of funds implemented from the biennial budget Funds implemented cumulatively at deliverable level (excluding PSC) Indicators: progress updated annually. Results are presented against biennial targets (Baselines are as of 31 December 2017) Highlights from the latest six-month reporting period Output name & statement Milestones: progress updated every six months Biennial budget & funds implemented cumulatively at Output level (excluding PSC) 10 Pandemic Influenza Preparedness Framework | ANNUAL PROGRESS REPORT | 1 January – 31 December 2018 IMPLEMENTED IMPLEMENTED IMPLEMENTED $3.5M $1.5M $1.9M countries from regions participated countries from regions participated countries from regions participated countries from regions participated countries from regions participated countries from regions participated regions involved PISA trainings completed Regional meetings held to improve global surveillance systems Laboratory trainings, missions and visits completed • WHO assessed the risk of 8 influenza A subtypes that caused zoonotic infections, including the first documented human A(H7N4) virus infection. Risk assessments were published to support countries in rapidly addressing emerging potential threats. • 12 countries including 1 PC recipient country reported severity assessments (PISA) to WHO. Another country initiated the process. Conducting severity assessments will inform national preparedness and response during yearly epidemics and future pandemics. • Of 194 WHO MS, 145 (75%) reported to FluNet and 119 (61%) to FluID. Most of these (≥95%) reported consistently during the influenza season (data not shown). WHO supports all countries to improve and sustain data reporting. • Of the 37 PC L&S recipient countries, the proportion reporting to FluNet (89%) and FluID (73%) exceeded the annual indicator targets. Consistent reporting facilitates ongoing situation monitoring. • 3 countries reported to FluNet and 11 reported to FluID for the first time in 2018. • Of the 136 countries participating in the 2018 EQAP, 116 (85%) correctly identified all non- seasonal viruses and 128 (94%) correctly identified all seasonal viruses.2 77 countries benefited from laboratory training activities. The EQAP and associated training efforts help sustain and improve virus detection capacity. • GISRS has grown to a network of 145 NICs in 115 countries. This includes NIC Armenia which was newly recognized in 2018. NICs are the backbone of GISRS. Outbreak detection & response trainings Trainings, missions & other types of support for surveillance provided Meetings, workshops, joint investigation & risk assessments Regional bulletins published DELIVERABLE A Risk and severity of influenza, including at the human-animal interface, are routinely assessed DELIVERABLE C Countries are supported to consistently report influenza data to global platforms DELIVERABLE B Quality influenza virus detection capacity is sustained MILESTONES MILESTONES MILESTONES 2018 EQAP status INDICATORS INDICATORS INDICATORS HIGHLIGHTS HIGHLIGHTS HIGHLIGHTS Number of WHO HAI risk assessments published Contract signed EQAP sent out Results received Results published in WER Results shared with participating laboratories Proportion of participating MS that were 100% correct for non-seasonal virus identification (N=136) Proportion of PC recipient MS reporting to FluNet (N=37)1 ANNUAL TARGET = 90% TARGET ≥ 85% 10 1330 34 Number of MS reporting PISA to WHO ≥ twice in a season 1 Proportion of participating MS that were 100% correct for seasonal virus identification (N=136) Proportion of PC recipient MS reporting to FluID (N=37)1 ANNUAL TARGET = 95% TARGET = 60% Laboratory & surveillance OUTPUT: National influenza L&S systems contribute to GISRS for timely risk assessment & response measure BIENNIAL BUDGET: $20.5M | IMPLEMENTED: $8.1M 30% 70% 40% 60% TARGET TARGETBASELINE BASELINE 68 308 68 226 76 5 140 5 77 6 54 6 98 6 86 6 4 9 9 63 85% 89% 94% 73% 49% 51% 20 12 11Pandemic Influenza Preparedness Framework | ANNUAL PROGRESS REPORT | 1 January – 31 December 2018 MILESTONES INDICATORS Laboratory & surveillance 34% 66% DELIVERABLE D Countries are supported to share timely representative influenza samples with WHO CCs countries from regions involved countries from regions Trainings on infectious substance shipping completed • 75% of countries (3 of 4) that reported zoonotic influenza cases to WHO, shared IVPP with GISRS according to WHO guidance.3 WHO systematically follows-up with countries on IVPP sharing. • 132 countries shared influenza viruses/clinical specimens with WHO CCs at least once. • Of 194 WHO MS, 84 (43%) shared viruses/clinical specimens with WHO CCs according to WHO guidance (two timely shipments).4 This was an increase of 14 countries since last year. • 108 countries made 268 shipments to WHO CCs. Shipments have doubled since 2014. • Staff from 41 countries were trained and certified to ship infectious substances to facilitate virus sharing. Shipments made using the SFP MILESTONES INDICATORS HIGHLIGHTS Protocols and guidance reviewed, including translations • GISRS characterized 605 viruses with pandemic potential. The viruses were of 10 influenza A subtypes and originated from 7 countries. The characterization led to the development of 4 new CVVs to enhance pandemic preparedness. • WHO updated 4 laboratory protocols5 and translated guidance documents into several languages (11 translations) to enable country utilization. Vaccine Composition Meeting consultations completed new CVVs proposed HIGHLIGHTSDELIVERABLE E Influenza CVVs, virus detection protocols and reagents, and reference materials are routinely updated N/A 36%N/A 44% IMPLEMENTED IMPLEMENTED $1.1M $93K TARGET TARGET TARGETBASELINE BASELINE BASELINE Number of zoonotic viruses & other viruses of pandemic potential characterized by GISRS N/A N/A 38% 62% 268 41 4 108 6 10 Proportion of MS with zoonotic influenza cases sharing IVPPs with GISRS (N=4) Proportion of MS with two timely shipments of virus isolates/clinical specimens with CCs (N=194)1 15 22 75% 43% 605 12 Pandemic Influenza Preparedness Framework | ANNUAL PROGRESS REPORT | 1 January – 31 December 2018 1 2 3 36 countries 15 BoD calculated countries 31 BoD findings published countries Implementation plan established DELIVERABLE B Disease burden findings are communicated to national and international expert bodies in a format that promotes evidence- based decision making • Four countries reported sharing their BOD estimates with national decision-making bodies. In 3 of these countries, the attention to influenza burden and influenza disease control led to updated initiatives. One country introduced seasonal influenza vaccination policy for risk groups and two countries updated their list of influenza risk groups. • Monitoring the progress on Deliverable B appears to be challenging. A periodic country survey is under consideration. • WHO is encouraging countries that calculated national influenza disease burden and used the estimates to influence national prevention and control policy to document the internal process from data to policy, highlighting strengths and challenges. MILESTONE INDICATORS HIGHLIGHTS Proportion of MS with burden of disease estimates that have been considered by NITAG or other decision-making bodies (N=19) 32% 68% countries countries countries 43 11 35 BOD calculated in BOD findings published in Burden of Disease OUTPUT: Influenza disease burden estimates are used for public health decisions BIENNIAL BUDGET: $2M | IMPLEMENTED: $728K DELIVERABLE A Representative national, regional and global disease burden estimates are available • In 2018, 14 countries published their BOD estimates bringing the total to 35 globally. The progress made has already exceeded the biennial indicator target highlighting the momentum gained in this area of work in recent years. In addition, 54 other countries have either already calculated or established a plan to estimate their BOD. • Regional and global BOD estimates help national and international decision-making bodies to take influenza preventive measures. To date, 55 countries including 29 low and middle income countries have shared their data for use in regional or global estimates. • WHO is trying to develop an influenza burden pyramid tool that can enable countries with limited data to estimate the comprehensive influenza burden. MILESTONE INDICATORS HIGHLIGHTS Number of MS with published disease burden estimates based on data collected since 20111 Num er of countries in each burden of disease estimate development stage Implementation plan established in countries Shared/communicated BOD estimates to decision-making bodies 4 IMPLEMENTED IMPLEMENTED $396K $332K 43% 57% TARGET TARGET BASELINE BASELINE 21 N/A 28 30% 35 16% 13Pandemic Influenza Preparedness Framework | ANNUAL PROGRESS REPORT | 1 January – 31 December 2018 Regulatory capacity building OUTPUT: Timely access to quality-assured influenza pandemic products is supported 27% 46% 73% 54% DELIVERABLE A National regulatory capacity for pandemic influenza products is strengthened DELIVERABLE B Adoption of regulatory pathways that accelerate approval for use of pandemic influenza products is promoted countries regions countries regions Refinements made to WHO Global benchmarking tool WHO regulatory preparedness guidelines translated to languages • PIP supports 16 countries to strengthen the 3 regulatory capacities critical for pandemic preparedness: regulatory system, marketing authorization and pharmacovigilance. • Progress has been made against the indicator target; regulatory capacities in 2 countries increased in maturity level based on WHO benchmarking assessments. One of these countries achieved maturity level 3 for all 3 capacities which is a major achievement resulting from PIP support and stakeholder commitment. • IDP implementation, benchmarking and follow-up visits continued in all 16 countries. All countries attended international workshops at stringent NRAs to improve knowledge and further advance IDP implementation. • Regulatory pathways to accelerate approval of products during emergencies include PQ and CRP. • Progress was made against the indicator target with 6 countries implementing their regulatory approach. This included defining and planning the information management and stakeholder coordination required for timely product approval in the broader pandemic preparedness context. • In 2018, 42 countries targeted by PIP, attended workshops or meetings on accelerated regulatory pathways. This awareness-raising resulted in one country signing the CRP agreement bringing the total to 37 countries/regulatory authorities having a CRP agreement. Country WHO benchmarked Country self-benchmarked IDP follow-up visits Workshops/trainings conducted to implement the PIP regulatory guidelines linking national IPPP & NVDP for pandemic influenza vaccines IDP implementation & technical support activities MILESTONES MILESTONES INDICATOR INDICATOR HIGHLIGHTS HIGHLIGHTS 1 1 5 5 5 11 166 5 2 15 Number of PC recipient MS which strengthened national regulatory capacity to oversee pandemic influenza products Number of PC recipient MS that have implemented a defined regulatory approach that enables timely approval for use of pandemic influenza products countries from regions 42 6 1 0 4 10 IMPLEMENTED IMPLEMENTED $423K $529K TARGET TARGET BASELINE BASELINE BIENNIAL BUDGET: $2.7M | IMPLEMENTED: $952K 3 6 14 Pandemic Influenza Preparedness Framework | ANNUAL PROGRESS REPORT | 1 January – 31 December 2018 MILESTONES MILESTONES Implementation of global partnerships & networks for effective RCCE capacity INDICATORS INDICATORS Partners identified Partners contacted Plan of action developed Evidence of approach alignment available 8 21 21 5 4 Risk Communications & Community Engagement BIENNIAL BUDGET: $2M | IMPLEMENTED: $771K OUTPUT: Tools and guidance are available for countries to enhance influenza risk communication and community engagement • OpenWHO.org gained nearly 6,500 new users, making it ahead of schedule to hit the biennial indicator target. OpenWHO now has 14 influenza related modules including “Pandemic Influenza Vaccines - National Deployment and Vaccination Plans.”6 • A social science intelligence network of partners and research groups activated and tracked community data during outbreaks while a new intelligence mapping tool was tested in 5 countries. Factors mapped include sociocultural, humanitarian and outbreak response. • A toolkit and guide for rapid sociocultural assessments was tested in 3 AFR countries. These would be quickly used during a pandemic. • RCCE doubled its training missions to include 54 countries from 3 regions. • Five AFR and EMR priority countries aligned their risk communication capacities within their Pandemic Preparedness Plans by drafting action plans, timelines and responsible units. • Global RCCE partners have expanded with the addition of OXFAM and Translators Without Borders to increase response strength and skills. • In 2019, 3 additional WHO regional offices will have RCCE technical focal points to support countries in preparedness planning. This will help roll-out global initiatives and facilitate implementation for country level impact. HIGHLIGHTS HIGHLIGHTS IMPLEMENTED IMPLEMENTED $361K $410K TARGET TARGET BASELINE BASELINE DELIVERABLE A Countries and front- line responders have access to resources for influenza risk communication, community engagement and social science-based interventions DELIVERABLE B Technical assistance is provided to countries to plan and exercise influenza risk communication and community engagement Trainings, missions and other type of technical support provided involving countries from regions 4 RCCE factors mapped in priority countries5 42% 58% Influenza guidance/courses available on OpenWHO OpenWHO advocacy & marketing events 14 16 3 475 0 12 500 100 Number of users who completed OpenWHO influenza modules1 Number of MS that utilized RCCE support for influenza preparedness or response 56 4 34% 66% 9 922 10 15Pandemic Influenza Preparedness Framework | ANNUAL PROGRESS REPORT | 1 January – 31 December 2018 Planning for Deployment OUTPUT: Plans for effective & efficient deployment of pandemic supplies are optimized DELIVERABLE A A common approach to manage global deployment operations is developed and regularly tested with stakeholders and deployment partners DELIVERABLE C Technical assistance to develop policies for sustainable influenza vaccine procurement and production is provided to countries DELIVERABLE B National deployment planning process is revised and updated IMPLEMENTED IMPLEMENTED $150K $129K PIP Deploy refinements to facilitate planning, allocation and coordination Global guidance tools revised Trainings, missions, visits & other types of technical support provided to update NVDP Trainings, missions, visits & other types of technical support provided • To support stakeholders refine pandemic product deployment plans, a PIP Deploy Gaming Exercise was developed to complement the simulation portal developed in 2014-17. The Gaming Exercise offers an immediate learning experience and tests the whole deployment cascade from country request to vaccine administration. • 2 regional workshops involving deployment simulation exercises are scheduled for February and April 2019, resulting in progress against the indicator target. • 6 advocacy events were held involving 20 countries and >20 global stakeholders. These events generate requests for support to update deployment plans. • Sustainability assessments allow countries to sustain local production (where applicable) and encourage national procurement of seasonal influenza vaccines with the goal of increasing pandemic preparedness. • The indicator target was achieved with 2 vaccine-producing countries completing assessments, bringing the total to 8 countries. One assessed country has begun implementing recommendations, including developing new national strategies for sustainable influenza vaccine production and use. • Through 2 meetings, support was provided to 42 countries to introduce the elements of sustainable production and procurement of influenza vaccines and the contribution to national and global pandemic preparedness. • 2 tools were launched to assist countries update their deployment plans; a training package and a set of 10 infographics based on WHO’s guidance.7 • An OpenWHO course based on the WHO guidance was launched. By January 2019, >1000 individuals registered for this course. • Technical support was provided to 11 countries to update plans and consider the sequence and timelines of deployment actions required in light of other response components. Challenges remain in coordination between regulatory, disease control and emergency response authorities. Future simulation exercises should help bring these stakeholders together. Advocacy meetings for a common approach completed MILESTONES MILESTONES MILESTONES INDICATOR INDICATOR HIGHLIGHTS HIGHLIGHTS HIGHLIGHTS 2 Annual simulation exercise conducted to test global deployment of pandemic influenza vaccines and other products Number of MS that have undergone a national analysis of influenza vaccine procurement or production sustainability Deliverable C activities are currently supported by US DHHS through Cooperative Agreement GH14-1420 between US CDC and WHO. PIP funds were not used to date. Milestone/indicator reporting continues as this Deliverable is within HLIP II scope and PC funds may be used in future. 3 2 6 8 1 3 2 6 Number of countries in each phase of the sustainability assessment process 1 2 3 4 5 1 Country engagement & concurrence 1 0 Stakeholders workshop held 1 Final sustainability assessment report Kick-off meeting completed 0 Draft report completed Country engagement & concurrence 1 4 2 5 3 Stakeholders workshop held Kick-off meeting completed Final sustainability assessment report available Draft report completed0 0 1 2 0 TARGET TARGET BASELINE BASELINE BIENNIAL BUDGET: $1.5M | IMPLEMENTED: $279K 18% 21% 82% 79% 1 8 countries regions countries regions countries 20 6 11 3 42 16 Pandemic Influenza Preparedness Framework | ANNUAL PROGRESS REPORT | 1 January – 31 December 2018 DELIVERABLE A Countries are supported to develop, test and update their pandemic influenza preparedness plan MILESTONES INDICATORS Influenza Pandemic Preparedness Planning OUTPUT: National pandemic influenza preparedness & response plans are updated in the context of all-hazards preparedness and global health security • 21 PC recipient countries have either written, exercised or are in the process of developing their influenza pandemic preparedness plans. Challenges to IPPP development include competing public health priorities and limited inter-sectoral attention to pandemic influenza preparedness. • Of 40 PC recipient countries, 14 (35%) now have a plan based on WHO’s Pandemic Influenza Risk Management guidance that was published in 2013. Pandemic plans strengthen country operational readiness and catalyze stakeholder commitment and coordination. • WHO published 3 operational guidance documents to support countries.8 Further guidance is under development including a package of exercise scenarios for testing IPPP and a guideline on non-pharmaceutical measures for mitigating the risk and impact of influenza. • 104 countries, including 20 PC recipient countries, participated in a WHO IPPP survey to identify planning needs. A report is being developed. An analysis of IPPP in context of the IHR (2005) and other disease response plans to provide countries with best planning practices is also being finalized. HIGHLIGHTS 25% 75% 30% 5%60% 30% Proportion of PC recipient MS that developed or updated a pandemic influenza preparedness plan since 2014 (N=40)1 Proportion of PC recipient MS that exercised their pandemic influenza preparedness plan in 2018 (N=40) Number of PC recipient MS currently developing/revising their IPPP IMPLEMENTED $557K Planning meeting held/workshop completed IPPP written or revised IPPP endorsed TARGET TARGETBASELINE BASELINE BIENNIAL BUDGET: $2.3M | IMPLEMENTED: $557K 1 2 3 12 5 0 10%35% IPPP exercises completed in5 countriesregions42 17Pandemic Influenza Preparedness Framework | ANNUAL PROGRESS REPORT | 1 January – 31 December 2018 PIP Framework Secretariat OUTPUT: The PIP Secretariat leads, manages and supports implementation of the PIP Framework 38% 62% DELIVERABLE A Promote the effective implementation of the PIP Framework in a changing environment DELIVERABLE C Negotiate and plan to operationalize the Standard Material Transfer Agreements 2 (SMTA2) DELIVERABLE B Collect, implement, monitor and report on the Partnership Contribution IMPLEMENTED IMPLEMENTED IMPLEMENTED $1.3M $808K $304K Meetings held and reports submitted to WHO DG or governing bodies to support implementation of section 7 of the PIP Framework With manufacturers of vaccines and/or antivirals With manufacturers of other pandemic related products With academic & research institutions Advocacy materials/events completed to promote the PIP Framework to stakeholders • Further to WHA71(11), the final text of the Analysis was published in December 2018 for discussion by EB144. • WHO worked closely with the PIP AG and WHO CCs to develop the Analysis on the scope of the PIP Framework. • WHO developed 7 Fact Sheets that concisely present basic information about specific topics related to the Analysis such as biosafety & biosecurity, GSD and databases, and new technologies.9 • Several talks and presentations on PIP were provided to Member States, academic institutions, technical gatherings and other fora. • 3 SMTA2s were concluded in 2018: one with influenza vaccine manufacturer Takeda (8% donation and 2% reserved pricing), one with influenza diagnostics manufacturer Becton Dickinson (25M syringe donation) and one with Weill Medical College of Cornell University. • To implement training offers received from academic and research institutions, WHO collaborated with the University of Siena to host a training workshop on Laboratory Quality Management and Biosafety for NICs.11 • PC invoices were issued in August 2018 and $15.2M (54%) were received by 31 December 2018. • Monitoring visits were conducted in all WHO regions. Discussions supported PIP recipient countries to refine implementation plans to focus on programmatic objectives, sustainability and progress against HLIP II indicators. • 19 ‘Highlights from the Field’ were published in the PIP newsletter to share news about PIP’s country impact. • The HLIP I final report was published to showcase the gains made in pandemic preparedness in 2014-2017.10 Social media and other fora were used to herald the report’s release. MILESTONES MILESTONES MILESTONES INDICATOR INDICATOR HIGHLIGHTS HIGHLIGHTS HIGHLIGHTS Proportion of Partnership Contributions received in year of invoice Proportion of companies reached to negotiate that signed an SMTA2 (N=32) 29 0 34% 100% ($28 M) 50% Status in annual project management cycle Number of SMTA2s in negotiation 2 0 3 65 Status of the Analysis requested by WHA 70(10) Fact sheets developed MS & other stakeholders consulted Information session held Analysis submitted to and discussed by EB144 (January 2019) Draft analysis published Analysis submitted to and discussed at WHA72 TARGET TARGET BASELINE BASELINE BIENNIAL BUDGET: $6.8M | IMPLEMENTED: $2.4M 25% 75% 35% 65% 10 Implementation Site monitoring visits 11 Planning Invoices sent by 30 June PC funds distributed by 31 December Monitoring Work plan compliance checks: Jan - June July - Dec Reporting PC implementation updates published in newsletter 20 54% 38% 3 7 3 3 18 Pandemic Influenza Preparedness Framework | ANNUAL PROGRESS REPORT | 1 January – 31 December 2018 Endnotes 1 Indicator baselines were first published in HLIP II in March 2018. Baseline data have since stabilized and 7 were updated. The changes are reflected in this report. 2 World Health Organization. Detection of influenza viruses by reverse transcription polymerase chain reaction: WHO external quality assessment programme summary analysis, 2018. Weekly Epidemiological Record. 2019; 94:5 (https://www.who.int/wer/2019/wer9405/en/, accessed 19 February 2019). 3 Operational Guidance on Sharing Influenza Viruses with Human Pandemic Potential (IVPP) under the Pandemic Influenza Preparedness (PIP) Framework. Geneva: World Health Organization; 2017 (https:// www.who.int/influenza/gisrs_laboratory/ivpp_sharing_guidance/en/, accessed 19 February 2019). 4 Operational Guidance on Sharing Seasonal Influenza viruses with WHO Collaborating Centres (CCs) under the Global Influenza Surveillance and Response System (GISRS). Geneva: World Health Organization; 2017 (https://www.who.int/influenza/gisrs_laboratory/seasonal_sharing_guide/en/, accessed 19 February 2019). 5 WHO information for molecular diagnosis of influenza virus. Geneva: World Health Organization; 2018 (https://www.who.int/influenza/gisrs_laboratory/molecular_diagnosis/en/, accessed 19 February 2019). Protocols updated: • Annex 2. B. Protocol 2: Real-time RT-PCR one-step duplex for the detection of Influenza type A subtype H1pdm09 and subtype H3 (Page 29) • Annex 2. D. Protocol 1: Real-time RT-PCR assays for the detection of seasonal influenza viruses and H5N1 influenza viruses (Page 34) • Annex 2. D. Protocol 2: Real-time RT-PCR for the detection of A(H5) gene (Page 39) • Annex 2. D. Protocol 3: Real-time RT-PCR procedures for the detection of influenza A, influenza B, A(H1N1), A(H3N2), A(H5N1), A(H7N9), A(H9N2) viruses (Page 41) 6 Pandemic Influenza Vaccines: National Deployment and Vaccination Plans. Geneva: World Health Organization; 2018 (https://openwho.org/courses/ndvp-en, accessed 19 February 2019). 7 Guidance on Development and Implementation of a National Deployment and Vaccination Plan for Pandemic Influenza Vaccines. Geneva: World Health Organization; 2012 (https://www.who.int/influenza_ vaccines_plan/resources/deployment/en/, accessed 19 February 2019). 8 Guidelines published in 2018 to support countries’ pandemic influenza preparedness • A checklist for pandemic influenza risk and impact management: building capacity for pandemic response. Geneva: World Health Organization; 2018 (https://www.who.int/influenza/preparedness/pandemic/ influenza_risk_management_checklist_2018/en/, accessed 19 February 2019). • Essential steps for developing or updating a national pandemic influenza preparedness plan. Geneva: World Health Organization; 2018 (https://www.who.int/influenza/preparedness/pandemic/essential_ steps_influenza/en/, accessed 19 February 2019). • A practical guide for developing and conducting simulation exercises to test and validate pandemic influenza preparedness plan. Geneva: World Health Organization; 2018 (https://www.who.int/influenza/ preparedness/pandemic/simex_influenza_preparedness_plans/en/, accessed 19 February 2019). 9 Information related to the development of the Analysis on seasonal influenza and GSD under the PIP Framework can be found here: http://www.who.int/influenza/pip/Documents_WHA70108b/en/. 10 Pandemic Influenza Preparedness Framework: Partnership Contribution High-Level Implementation Plan I. Final Report 2014-2017. Geneva: World Health Organization; 2018 (https://www.who.int/influenza/pip/ partnership_contribution/hlipi_final_report/en/, accessed 19 February 2019). 11 For more information on the training workshop see: https://www.who.int/influenza/Sienna_Workshop_ Report.pdf?ua=1 ANNEX A: FINANCIAL REPORT 20 Pandemic Influenza Preparedness Framework | ANNUAL PROGRESS REPORT | 1 January – 31 December 2018 CONTRIBUTORS Grand Total with PSC TOTAL CONTRIBUTIONS (US$) $169 623 865 ($152 551 038, net of PSC) Glaxosmithkline (GSK) Sanofi Pasteur Hoffmann - La Roche and Co. Ltd. Novartis Medimmune Seqirus Kaketsuken (K M Biologics) The Research Foundation for Microbial Disease of Osaka University (BIKEN) CSL Limted Denka Seiken Co. Ltd. Kitasato Daiichi Sankyo Vaccine Co. Ltd. Green Cross Corporation Shanghai Institute of Biological Products Co., Ltd. Sinovac Biotech Ltd. Becton Dickinson and Company (BD) Beijing Tiantan Biological Procucts Co. Ltd. Fluart Innovative Vaccines LTD Baxter International Inc. Changchun Institute of Biological Products Co., Ltd. CNBG Omninvest Vaccine Manufacturing, Researching & Trading Ltd. S K Bioscience Alere Inc. Saint-Petersburg Scientific Research Institute of Vaccines & Sera Focus Diagnostics, Inc. Adimmune Corporation Qiagen Serum Institute of India Ltd. DiaSorin Molecular LLC China National Biotec Group Vabiotech Cadila Healthcare Ltd. (R&D Center) Government Pharmaceutical Organization (GPO) Princeton Biomeditech Corporation Institute of Vaccines and Medical Biologicals (IVAC) Cepheid Takeda Pharmaceuticals Internatioanl GmbH Fast Track Diagnostics Quidel Corporation NPO Petrovax Pharm Indevr, Inc. Medicago Inc. Response Biomedical Corporation Nanotherapeutics Nanosphere Inc. PT Bio Farma (Persero) Protein Sciences Corporation UMN Pharm INC. Lanzhou Institute of Biological Products 40 909 080 39 569 520 39 960 031 15 292 743 7 246 929 7 215 830 3 611 092 3 596 419 2 667 745 2 589 088 1 936 830 1 642 357 556 575 556 575 326 432 262 223 307 379 209 205 208 231 149 443 122 678 117 159 86 815 83 844 65 543 61 512 35 623 29 692 20 000 12 761 15 170 13 045 10 591 10 591 10 591 37 580 13 045 8 136 10 246 7 439 7 439 5 417 5 337 4 984 4 984 4 944 2 799 2 173 Table A.1: Partnership Contribution received from each manufacturer 2012–2018 21Pandemic Influenza Preparedness Framework | ANNUAL PROGRESS REPORT | 1 January – 31 December 2018 Ta bl e A. 2: Fu nd a llo ca tio n an d ex pe nd itu re fo r st af f a nd a ct iv iti es 1 Ja nu ar y - 31 D ec em be r 2 01 8 To ta l f or B OD To ta l f or R EG To ta l f or R CC E R is k an d s ev er ity o f i nfl ue nz a ar e ro ut in el y as se ss ed Q ua lit y in flu en za v ir us d et ec tio n ca p ac ity is s us ta in ed C o un tr ie s ar e su p p o rt ed to c o ns is te nt ly re p o rt in flu en za d at a to g lo b al pl at fo rm s C o un tr ie s ar e su p p o rt ed to s ha re ti m el y re p re se nt at iv e in flu en za sa m pl es w ith W HO C Cs In flu en za C V V s, v ir us d et ec tio n p ro to co ls a nd re fe re nc e m at er ia ls a re ro ut in el y u pd at ed 7 0 85 48 1 3 6 81 10 3 3 4 98 85 5 18 2 2 48 95 % 6 2 64 85 1 3 1 89 42 6 1 8 77 71 0 1 3 11 71 6 59 % 3 6 75 87 6 1 9 31 08 8 1 4 86 82 5 44 4 2 63 77 % 3 2 51 97 6 93 2 1 79 1 5 88 75 0 85 0 8 52 42 5 4 26 36 1 1 84 64 24 2 79 4 3 75 42 2 9 64 37 1 4 11 48 6 0 90 39 6 2 45 89 84 5 1 0 34 17 9 1 1 42 75 0 1 2 10 29 1 60 5 1 46 41 0 5 82 19 4 5 64 63 1 3 75 52 9 0 49 10 2 3 26 49 7 0 90 33 1 5 97 16 5 4 93 1 6 68 98 8 1 1 10 96 8 55 8 0 20 67 % 24 7 9 98 12 3 9 99 93 47 7 30 52 2 75 % 82 % 53 % 85 % 67 % 84 % 68 % 20 52 6 1 82 1 9 66 35 8 2 7 31 50 0 2 0 61 14 3 1 0 30 57 2 77 1 7 66 25 8 8 06 1 4 25 75 0 95 2 0 13 47 3 7 37 98 3 1 80 72 7 8 42 25 5 3 38 10 59 4 6 04 8 0 67 83 5 2 5 26 76 9 76 % 74 % 67 % 75 % La bo ra to ry & Su rv ei lla nc e O UT PU T DE LI VE RA BL E 20 18 -1 9 A p p ro ve d bu dg et Fu nd s di st rib ut ed fo r 2 01 8 Ex pe nd itu re 20 18 Im pl em en ta tio n on 2 01 8 fu nd s d is tr ib ut ed (% ) Ba la nc e fu nd s Re p re se nt at iv e na tio na l, re g io na l & g lo b al d is ea se b ur d en e st im at es ar e av ail ab le D is ea se b ur d en fi nd in g s ar e co m m un ic at ed to n at io na l a nd in te rn at io na l e xp er t b od ie s i n a f or m at th at p ro m ot es e vid en ce -b as ed de cis io n m ak in g Bu rd en o f Di se as e N at io na l r eg ul at o ry c ap ac ity fo r p an d em ic in flu en za p ro d uc ts is str en gt he ne d Ad op tio n of re gu lat or y p at hw ay s t ha t a cc el er at e ap pr ov al fo r u se o f p an d em ic in flu en za p ro d uc ts is p ro m o te d Re gu lat or y Ca pa cit y Co un tri es an d fro nt -li ne re sp on de rs ha ve ac ce ss to g ui da nc e, to ol s a nd in te ra ct ive re so ur ce s f or ri sk co m m un ica tio n, co m m un ity en g ag em en t, an d s o ci al s ci en ce -b as ed in te rv en tio ns fo r in flu en za Te ch ni ca l a ss ist an ce fo r r isk co m m un ica tio n, co m m un ity e ng ag em en t & s o ci al s ci en ce -b as ed in te rv en tio ns p ro vi d ed to c o un tr ie s to fa ci lit at e in flu en za in te rv en tio ns & a d d re ss v ac ci ne h es ita nc y Ri sk C om m un ica tio n & Co m m un ict y En ga ge m en t To ta l f or L& S 22 Pandemic Influenza Preparedness Framework | ANNUAL PROGRESS REPORT | 1 January – 31 December 2018 a F un d s ar e b ei ng d is tr ib ut ed fo r 2 01 9 w o rk p la n im p le m en ta tio n. b Un d is tr ib ut ed fu nd s in cl ud e Pa rt ne rs hi p C o nt rib ut io ns re ce iv ed a ft er fu nd s fo r 2 01 8 w o rk p la ns w er e d is tr ib ut ed . c I nc lu d es R es p o ns e Fu nd s (U S$ 4 6, 72 7, 03 6) w hi ch w ill o nl y b e us ed a t t he t im e o f a p an d em ic . A co m m on ap pr oa ch to m an ag e gl ob al de pl oy m en t o pe ra tio ns is de ve lo pe d an d re gu lar ly te ste d wi th st ak eh ol de rs an d de pl oy m en t pa rtn er s N at io na l d ep lo ym en t p la nn in g p ro ce ss is re vi se d & u p d at ed Te ch ni ca l a ss is ta nc e to d ev el o p p o lic ie s fo r su st ai na b le in flu en za va cc in e pr oc ur em en t a nd p ro du ct io n is pr ov id ed to co un tri es Pr o m o te th e ef fe ct iv e im p le m en ta tio n o f t he P IP F ra m ew o rk in a ch an gi ng e nv iro nm en t C o lle ct , i m p le m en t, m o ni to r & re p o rt o n th e Pa rt ne rs hi p C o nt ri b ut io n N eg o tia te a nd p la n to o p er at io na liz e th e St an d ar d M at er ia l T ra ns fe r Ag re em en ts 2 (S M TA 2) Re sp o ns e fu nd s A nn ua l i nt er es t e ar ne d o n re sp o ns e fu nd s fo r 20 18 Pl an ni ng fo r De pl oy m en t PI P Se cr et ar iat Co un tri es ar e su pp or te d to d ev el op , te st an d up da te th ei r p an de m ic in flu en za p re p ar ed ne ss a nd re sp o ns e p la n 31 06 9 5 00 6 8 08 96 6 2 8 42 69 1 2 3 72 11 9 47 0 5 72 3 7 87 8 46 6 15 92 9 5 15 2 4 18 3 17 4 4 73 3 3 31 6 77 63 7 1 47 6 1 82 30 8 3 75 3 25 7 1 49 36 9 2 62 13 78 9 5 81 2 36 8 1 15 8 15 7 9 96 1 54 7 11 35 5 2 48 1 5 51 1 92 4 4 57 4 2 67 79 ,7 15 ,5 25 c 71 % 83 % 64 % In fl u en za P an d em ic Pr ep ar ed ne ss Pl an ni ng To ta l fo r P re pa re dn es s O ut pu ts PS C (1 3% ) o n Pr ep ar ed ne ss F un d s In p ro ce ss fo r 2 01 9 di str ib ut io na Un di str ib ut ed fu nd sb To ta l fo r P IP Se cre ta ria t O ut pu t PS C (1 3% ) o n Se cr et ar ia t F un d s In p ro ce ss fo r 2 01 9 di str ib ut io na Un di str ib ut ed fu nd sb Gr an d To ta l f or P IP P C 31 06 9 5 00 20 66 2 8 46 12 83 1 4 30 62 % 29 77 8 9 93 To ta l f or D EP To ta l f or IP PP Gr an d To ta l f or Pr ep ar ed ne ss 81 4 1 00 40 7 0 50 14 9 9 97 25 7 0 53 10 3 5 00 51 75 0 – 51 75 0 61 4 1 00 2 2 52 61 7 3 3 03 59 1 1 3 90 76 9 1 2 20 85 8 16 9 9 11 2 2 94 79 2 97 7 5 84 80 7 7 19 16 9 8 65 1 2 10 58 3 47 4 3 38 34 3 5 42 13 0 7 96 1 1 29 55 9 55 6 8 54 57 2 7 05 30 7 0 50 12 8 9 41 17 8 1 09 37 % 0%42 % 49 % 72 % 83 % 88 % 1 5 31 70 0 2 2 52 61 7 1 12 9 5 59 55 6 8 54 57 2 7 05 76 5 8 50 27 8 9 38 48 6 9 12 36 % 49 % O UT PU T DE LI VE RA BL E 20 18 -1 9 A p p ro ve d bu dg et Fu nd s di st rib ut ed fo r 2 01 8 Ex pe nd itu re 20 18 Im pl em en ta tio n on 2 01 8 fu nd s d is tr ib ut ed (% ) Ba la nc e fu nd s Gr an d To ta l f or P IP Se cr et ar iat Gr an d To ta l f or R es po ns e F un ds 6 80 8 9 66 3 52 0 3 28 2 68 0 4 94 76 % 3 20 9 4 96 45 79 8 4 49 92 8 5 87 46 72 7 0 36 – – – – 23Pandemic Influenza Preparedness Framework | ANNUAL PROGRESS REPORT | 1 January – 31 December 2018 Fig. A.1: Interim certified financial statement as of 31 December 2018
World Health Organization 20 Avenue Appia 1211 Geneva 27 Switzerland PIP Framework Secretariat pipframework@who.int www.who.int/influenza/pip/en